Preclinical Models of Brain Metastases in Breast Cancer

Breast cancer remains a leading cause of mortality among women worldwide. Brain metastases confer extremely poor prognosis due to a lack of understanding of their specific biology, unique physiologic and anatomic features of the brain, and limited treatment strategies. A major roadblock in advancing...

Descripción completa

Detalles Bibliográficos
Autores principales: Knier, Natasha N., Pellizzari, Sierra, Zhou, Jiangbing, Foster, Paula J., Parsyan, Armen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945440/
https://www.ncbi.nlm.nih.gov/pubmed/35327469
http://dx.doi.org/10.3390/biomedicines10030667
_version_ 1784673959053099008
author Knier, Natasha N.
Pellizzari, Sierra
Zhou, Jiangbing
Foster, Paula J.
Parsyan, Armen
author_facet Knier, Natasha N.
Pellizzari, Sierra
Zhou, Jiangbing
Foster, Paula J.
Parsyan, Armen
author_sort Knier, Natasha N.
collection PubMed
description Breast cancer remains a leading cause of mortality among women worldwide. Brain metastases confer extremely poor prognosis due to a lack of understanding of their specific biology, unique physiologic and anatomic features of the brain, and limited treatment strategies. A major roadblock in advancing the treatment of breast cancer brain metastases (BCBM) is the scarcity of representative experimental preclinical models. Current models are predominantly based on the use of animal xenograft models with immortalized breast cancer cell lines that poorly capture the disease’s heterogeneity. Recent years have witnessed the development of patient-derived in vitro and in vivo breast cancer culturing systems that more closely recapitulate the biology from individual patients. These advances led to the development of modern patient-tissue-based experimental models for BCBM. The success of preclinical models is also based on the imaging technologies used to detect metastases. Advances in animal brain imaging, including cellular MRI and multimodality imaging, allow sensitive and specific detection of brain metastases and monitoring treatment responses. These imaging technologies, together with novel translational breast cancer models based on patient-derived cancer tissues, represent a unique opportunity to advance our understanding of brain metastases biology and develop novel treatment approaches. This review discusses the state-of-the-art knowledge in preclinical models of this disease.
format Online
Article
Text
id pubmed-8945440
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89454402022-03-25 Preclinical Models of Brain Metastases in Breast Cancer Knier, Natasha N. Pellizzari, Sierra Zhou, Jiangbing Foster, Paula J. Parsyan, Armen Biomedicines Review Breast cancer remains a leading cause of mortality among women worldwide. Brain metastases confer extremely poor prognosis due to a lack of understanding of their specific biology, unique physiologic and anatomic features of the brain, and limited treatment strategies. A major roadblock in advancing the treatment of breast cancer brain metastases (BCBM) is the scarcity of representative experimental preclinical models. Current models are predominantly based on the use of animal xenograft models with immortalized breast cancer cell lines that poorly capture the disease’s heterogeneity. Recent years have witnessed the development of patient-derived in vitro and in vivo breast cancer culturing systems that more closely recapitulate the biology from individual patients. These advances led to the development of modern patient-tissue-based experimental models for BCBM. The success of preclinical models is also based on the imaging technologies used to detect metastases. Advances in animal brain imaging, including cellular MRI and multimodality imaging, allow sensitive and specific detection of brain metastases and monitoring treatment responses. These imaging technologies, together with novel translational breast cancer models based on patient-derived cancer tissues, represent a unique opportunity to advance our understanding of brain metastases biology and develop novel treatment approaches. This review discusses the state-of-the-art knowledge in preclinical models of this disease. MDPI 2022-03-13 /pmc/articles/PMC8945440/ /pubmed/35327469 http://dx.doi.org/10.3390/biomedicines10030667 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Knier, Natasha N.
Pellizzari, Sierra
Zhou, Jiangbing
Foster, Paula J.
Parsyan, Armen
Preclinical Models of Brain Metastases in Breast Cancer
title Preclinical Models of Brain Metastases in Breast Cancer
title_full Preclinical Models of Brain Metastases in Breast Cancer
title_fullStr Preclinical Models of Brain Metastases in Breast Cancer
title_full_unstemmed Preclinical Models of Brain Metastases in Breast Cancer
title_short Preclinical Models of Brain Metastases in Breast Cancer
title_sort preclinical models of brain metastases in breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945440/
https://www.ncbi.nlm.nih.gov/pubmed/35327469
http://dx.doi.org/10.3390/biomedicines10030667
work_keys_str_mv AT kniernatashan preclinicalmodelsofbrainmetastasesinbreastcancer
AT pellizzarisierra preclinicalmodelsofbrainmetastasesinbreastcancer
AT zhoujiangbing preclinicalmodelsofbrainmetastasesinbreastcancer
AT fosterpaulaj preclinicalmodelsofbrainmetastasesinbreastcancer
AT parsyanarmen preclinicalmodelsofbrainmetastasesinbreastcancer